HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Cocrystal Pharma (NASDAQ:COCP) and maintained a $12 price target.
June 02, 2023 | 10:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cocrystal Pharma (NASDAQ:COCP) receives a reiterated Buy rating and a maintained $12 price target from HC Wainwright & Co. analyst Raghuram Selvaraju.
The reiterated Buy rating and maintained $12 price target by HC Wainwright & Co. analyst Raghuram Selvaraju is a positive signal for Cocrystal Pharma. This reaffirms the analyst's confidence in the company's potential, which could lead to increased investor interest and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100